Naratriptan Chanelle Dosage/Direction for Use

Posology: Naratriptan is recommended as monotherapy for the acute treatment of a migraine attack.
Naratriptan should not be used prophylactically.
Naratriptan should be swallowed whole with water.
Adults (18-65 years of age): The recommended dose of Naratriptan is a single 2.5 mg tablet.
The total dose should not exceed two 2.5 mg tablets in any 24-hour period.
If symptoms of migraine should recur, following an initial response, a second dose may be taken provided that there is a minimum interval of four hours between the two doses.
If a patient does not respond to a first dose of Naratriptan a second dose should not be taken for the same attack, as it is unlikely to be of benefit. However Naratriptan may be used for subsequent migraine attacks.
Adolescents (12-17 years of age): Efficacy of Naratriptan at single doses of 0.25, 1.0 and 2.5 mg was not demonstrated to be greater than placebo in a placebo-controlled study in adolescents (12 to 17 years). Therefore, the use of Naratriptan in patients under 18 years of age is not recommended.
Children (under 12 years of age): There are no data available on the use of naratriptan in children under 12 years of age therefore its use in this age group is not recommended.
Elderly (over 65 years of age): The safety and efficacy of naratriptan in individuals over age 65 has not yet been established and therefore, its use in this age group cannot be recommended. There is a moderate decrease in clearance with age (see Pharmacology: Pharmacokinetics under Actions).
Renal Impairment: Naratriptan should be used with caution in patients with renal impairment. The maximum dose in any 24-hour treatment period is a single 2.5 mg tablet. The use of Naratriptan is contraindicated in patients with severe renal impairment (creatinine clearance < 15 ml/min) (see Contraindications and Pharmacology: Pharmacokinetics under Actions).
Hepatic Impairment: Naratriptan should be used with caution in patients with hepatic impairment. The maximum dose in any 24-hour treatment period is a single 2.5 mg tablet. The use of Naratriptan is contraindicated in patients with severe hepatic impairment (Child-Pugh grade C) (see Contraindications and Pharmacology: Pharmacokinetics under Actions).